ABSTRACT
Cathelicidin peptide LL-37 plays an important role in the early host response against invading pathogens via its broad-spectrum anti-microbial activity. In this study, we investigated LL-37 expression in the inflamed mucosa of inflammatory bowel disease (IBD) patients. Furthermore, the regulatory mechanism of LL-37 induction was investigated in human colonic subepithelial myofibroblasts (SEMFs). LL-37 mRNA expression and protein secretion were analysed using real-time polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. Intracellular signalling pathways were analysed using immunoblotting and specific small interference RNA (siRNA). The expression of LL-37 mRNA was increased significantly in the inflamed mucosa of ulcerative colitis and Crohn's disease. The Toll-like receptor (TLR)-3 ligand, polyinosinic-polycytidylic acid (poly(I:C), induced LL-37 mRNA expression and stimulated LL-37 secretion in colonic SEMFs. The transfection of siRNAs specific for intracellular signalling proteins [Toll/IL-1R domain-containing adaptor-inducing interferon (IFN) (TRIF), tumour necrosis factor receptor-associated factor (TRAF)6, transforming growth factor ß-activated kinase (TAK)1] suppressed the poly(I:C)-induced LL-37 mRNA expression significantly. Poly(I:C)-induced phosphorylation of mitogen-activated protein kinases (MAPKs) and activated nuclear factor kappa B (NF-κB) and activating factor protein (AP)-1. siRNAs specific for NF-κB and c-Jun inhibited poly(I:C)-induced LL-37 mRNA expression. LL-37 suppressed lipopolysaccharide (LPS)-induced interleukin (IL)-6 and IL-8 expression significantly in colonic SEMFs. The expression of LL-37 was up-regulated in the inflamed mucosa of IBD patients. LL-37 was induced by TLR-3 stimulation and exhibited an anti-microbial effect via interaction with lipopolysaccharide (LPS).
Subject(s)
Antimicrobial Cationic Peptides/genetics , Gene Expression Regulation , Inflammatory Bowel Diseases/genetics , Adaptor Proteins, Vesicular Transport/metabolism , Antimicrobial Cationic Peptides/metabolism , Biomarkers , Colon , Cytokines/metabolism , Humans , Immunohistochemistry , Inflammation Mediators/metabolism , Inflammatory Bowel Diseases/immunology , Inflammatory Bowel Diseases/metabolism , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Intracellular Signaling Peptides and Proteins , MAP Kinase Kinase Kinases/metabolism , Myofibroblasts/metabolism , Poly I-C/immunology , Signal Transduction , TNF Receptor-Associated Factor 6/metabolism , CathelicidinsSubject(s)
Intestines/pathology , Lymphocytes/metabolism , Sezary Syndrome/immunology , Skin Neoplasms/pathology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Colectomy/methods , Drug Therapy/methods , Fatal Outcome , Humans , Intestines/surgery , Male , Middle Aged , Sezary Syndrome/diagnosis , Sezary Syndrome/drug therapyABSTRACT
Despite the importance of taking the primary dental impression, this act remains unfortunately neglected by most practitioners. Think to succeed a total removable prosthesis from a failed primary dental impression is a challenge for the practitioner and seems utopia. For this, you wish through our work give the importance to the choice of the mass-produced impression tray that is paramount for the success of the primary dental impression. This study examines a sample of 160 plaster primary models (80 maxillary and 80 mandibular) from primary dental impression carried out with mass-produced impression trays whether or not modified for new total edentulous patients having consulted at the University Dental centre in Casablanca for a prosthetic rehabilitation by total prosthesis. Thirty-six women and 44 men have been selected. The study showed that men have maxillary and mandibular arches longer and wider than those of women, and that the average value for several parameters measured is close to the measurements of the maxilla trays U3 and mandibular L3; Where the need for acquisition of large size dental impression tray, in accordance with the dimensions of our population in order to meet our expectations, namely: to respect the integrity of the support surfaces, to meet the mechanical qualities of the prosthesis, to restore the aesthetics and function by minimizing the grievances of the toothless total subject.
Subject(s)
Cephalometry/methods , Dental Arch/pathology , Jaw, Edentulous/pathology , Cross-Sectional Studies , Cuspid/pathology , Dental Impression Technique/instrumentation , Denture Design , Equipment Design , Esthetics, Dental , Female , Humans , Male , Mandible/pathology , Maxilla/pathology , Models, Dental , Morocco , Palate/pathology , Sex FactorsABSTRACT
Eotaxins induce the trafficking of eosinophils to the sites of inflammation via CC chemokine receptor 3 (CCR3). In this study, we investigated eotaxin-3/CC chemokine ligand 26 (CCL26) expression in the inflamed mucosa of patients with inflammatory bowel disease (IBD), and characterized the molecular mechanisms responsible for eotaxin-3 expression in human colonic myofibroblasts. Eotaxin-3 mRNA and protein expression was evaluated by real time-polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. Eotaxin-3 mRNA expression was elevated significantly in the active lesions of ulcerative colitis (UC) patients. Significant elevations were also observed in the active lesions of Crohn's disease (CD) patients, but this was significantly lower than that detected in the active UC lesions. There were no significant increases in the inactive lesions of UC or CD patients. Colonic myofibroblasts were identified as a major source of eotaxin-3 in the colonic mucosa, and interleukin (IL)-4 and IL-13 enhanced eotaxin-3 mRNA and protein expression significantly in these cells. There was a significant positive correlation between mucosal eotaxin-3 and IL-4 mRNA expression in the active lesions of IBD patients. The IL-4- and IL-13-induced eotaxin-3 mRNA expression was regulated by the signal transducer and activator of transcription-6 (STAT-6) and suppressor of cytokine signalling (SOCS)1-mediated pathways. Interferon (IFN)-γ acts as a negative regulator on the IL-4- and IL-13-induced eotaxin-3 expression via STAT-1 activation. Eotaxin-3 expression was elevated specifically in the active lesions of IBD, in particular UC. Eotaxin-3 derived from colonic myofibroblasts may play an important role in the pathophysiology of UC.
Subject(s)
Chemokines, CC/metabolism , Cytokines/immunology , Inflammatory Bowel Diseases/immunology , Intestinal Mucosa/immunology , Myofibroblasts/immunology , Th2 Cells/immunology , Cells, Cultured , Chemokine CCL26 , Chemokines, CC/genetics , Colon/pathology , Humans , Myofibroblasts/pathology , RNA, Messenger/analysis , Receptors, CCR3/metabolism , STAT6 Transcription Factor/metabolism , Signal Transduction , Suppressor of Cytokine Signaling 1 Protein , Suppressor of Cytokine Signaling Proteins/metabolism , Up-RegulationABSTRACT
Interleukin (IL)-37 is a member of the IL-1 cytokine family. We investigated IL-37b expression in the inflamed mucosa of inflammatory bowel disease (IBD) patients. Furthermore, we analysed IL-37b expression in human colonic epithelial cells. The human colonic epithelial cell line T84 and human colonic subepithelial myofibroblasts (SEMFs) were used. IL-37b expression in the IBD mucosa was evaluated by immunohistochemistry. IL-37b mRNA and protein expression were determined by real time-polymerase chain reaction (PCR) and Western blotting, respectively. IL-37b was not detected in the normal colonic mucosa. In the inflamed mucosa of IBD patients, epithelial IL-37b expression was increased markedly. In ulcerative colitis (UC) and Crohn's disease (CD) patients, IL-37b expression was enhanced in the affected mucosa. In the intestinal epithelial cell line T84, the expression of IL-37b mRNA and protein was enhanced by tumour necrosis factor (TNF)-α. This IL-37b induction by TNF-α was mediated by nuclear factor (NF)-κB and activator protein (AP)-1 activation. Furthermore, IL-37b inhibited TNF-α-induced interferon-γ-inducible protein (IP)-10 expression significantly in human colonic SEMFs. Epithelial IL-37b expression was increased in IBD patients, especially UC patients. IL-37b may be involved in the pathophysiology of IBD as an anti-inflammatory cytokine and an inhibitor of both innate and acquired immune responses.
Subject(s)
Inflammatory Bowel Diseases/immunology , Interleukin-1/metabolism , Adaptive Immunity , Caco-2 Cells , Case-Control Studies , Cells, Cultured , Chemokine CXCL10/genetics , Chemokine CXCL10/metabolism , Colitis, Ulcerative/genetics , Colitis, Ulcerative/immunology , Colitis, Ulcerative/metabolism , Colitis, Ulcerative/pathology , Crohn Disease/genetics , Crohn Disease/immunology , Crohn Disease/metabolism , Crohn Disease/pathology , Gene Expression/drug effects , Humans , Immunity, Innate , Inflammatory Bowel Diseases/genetics , Inflammatory Bowel Diseases/metabolism , Inflammatory Bowel Diseases/pathology , Interleukin-1/genetics , Intestinal Mucosa/drug effects , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , MAP Kinase Signaling System , Myofibroblasts/drug effects , Myofibroblasts/immunology , Myofibroblasts/metabolism , Myofibroblasts/pathology , NF-kappa B/metabolism , Phosphatidylinositol 3-Kinases/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Transcription Factor AP-1/metabolism , Tumor Necrosis Factor-alpha/pharmacologyABSTRACT
Recent studies have demonstrated that the complement system participates in the regulation of T cell functions. To address the local biosynthesis of complement components in inflammatory bowel disease (IBD) mucosa, we investigated C3 and interleukin (IL)-17 mRNA expression in mucosal samples obtained from patients with IBD. The molecular mechanisms underlying C3 induction were investigated in human colonic subepithelial myofibroblasts (SEMFs). IL-17 and C3 mRNA expressions in the IBD mucosa were evaluated by real-time polymerase chain reaction. The C3 levels in the supernatant were determined by enzyme-linked immunosorbent assay. IL-17 and C3 mRNA expressions were elevated significantly in the active lesions from ulcerative colitis (UC) and Crohn's disease (CD) patients. There was a significant positive correlation between IL-17 and C3 mRNA expression in the IBD mucosa. IL-17 stimulated a dose- and time-dependent increase in C3 mRNA expression and C3 secretion in colonic SEMFs. The C3 molecules secreted by colonic SEMFs were a 115-kDa alpha-chain linked to a 70-kDa beta-chain by disulphide bonds, which was identical to serum C3. The IL-17-induced C3 mRNA expression was blocked by p42/44 mitogen-activated protein kinase (MAPK) inhibitors (PD98059 and U0216) and a p38 MAPK inhibitor (SB203580). Furthermore, IL-17-induced C3 mRNA expression was inhibited by an adenovirus containing a stable mutant form of I kappaB alpha. C3 and IL-17 mRNA expressions are enhanced, with a strong correlation, in the inflamed mucosa of IBD patients. Part of these clinical findings was considered to be mediated by the colonic SEMF response to IL-17.
Subject(s)
Colitis, Ulcerative/immunology , Complement C3/immunology , Crohn Disease/immunology , Gene Expression Regulation/immunology , Interleukin-17/immunology , Intestinal Mucosa/immunology , RNA, Messenger/immunology , Adenoviridae , Colitis, Ulcerative/genetics , Colitis, Ulcerative/metabolism , Colitis, Ulcerative/pathology , Colon/immunology , Colon/metabolism , Colon/pathology , Complement C3/biosynthesis , Complement C3/genetics , Crohn Disease/genetics , Crohn Disease/metabolism , Crohn Disease/pathology , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Female , Flavonoids , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , Humans , I-kappa B Proteins/genetics , I-kappa B Proteins/immunology , I-kappa B Proteins/metabolism , Imidazoles/pharmacology , Interleukin-17/biosynthesis , Interleukin-17/genetics , Interleukin-17/pharmacology , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Male , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 1/genetics , Mitogen-Activated Protein Kinase 1/immunology , Mitogen-Activated Protein Kinase 1/metabolism , Mutation , NF-KappaB Inhibitor alpha , Pyridines/pharmacology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods , Time Factors , Transduction, Genetic , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/genetics , p38 Mitogen-Activated Protein Kinases/immunology , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
OBJECTIVE: The purpose of this systematic literature review is to determine the impact of implant length on marginal bone loss in atrophied arches. MATERIAL AND METHODS: The systematic search of the literature was carried out using electronic databases PubMed, EbscoHost, Cochrane, as well as a manual search of randomized controlled trials in humans, with a follow-up period of at least 12 months, published between 2005 and 2016, comparing the short implants on the one hand, and the long implants placed in atrophic bone crests having undergone bone augmentation on the other hand. This systematic review followed the guidelines of PRISMA Statement (Preferred Reporting Items for Systematic Reviews and Meta-Analyzes). The results of the clinical trials were described according to the PICO criteria. The qualitative analysis was conducted by Jadad scale and the Cochrane Collaboration's tool for assessing risk of bias. RESULTS: Thirteen randomized controlled trials (RCTs) were included in our systematic review. Gradual marginal bone loss (intra-group comparison) was significant regardless of the arcade. The difference in bone loss between short and long implants (inter-group comparison) was not significant in the first year, but became significant at the end of the fifth year regardless of the arcade. CONCLUSION: Despite the satisfactory results in relation to short implants, it is appropriate to extend the duration of RCTs up to 10 years in order to support the data collected in our systematic review.
Subject(s)
Alveolar Ridge Augmentation , Dental Implants , Dental Implantation, Endosseous , Dental Prosthesis Design , Dental Prosthesis, Implant-Supported , Dental Restoration Failure , Humans , Mandible , MaxillaABSTRACT
BACKGROUND AND AIM: As a tool for examining the small intestine, double-balloon enteroscopy (DBE) has been used routinely. However, there remain a few issues relating to the handling of DBE, such as attaching a balloon to the tip of the scope, and inflating/deflating the two balloon systems. Recently, we developed a novel single-balloon enteroscopy (SBE) system for the examination of the small intestine. The aim of the present study was to evaluate the insertion technique, the safety, and the clinical impact of the SBE system. PATIENTS AND METHODS: Between January 2006 and June 2007, all patients undergoing enteroscopy with the Olympus SBE system (length 200 cm, outer diameter 9.2 mm) were studied. Instead of a balloon attached to the distal scope end, the distal scope end was hook-shaped, and manipulating the up-angle or down-angle of the scope end enabled exploration of the small intestine. RESULTS: A total of 78 procedures were performed in 41 patients (24 men, 17 women; mean age 48.9 years, range 23 - 85 years). The indications for the examination were suspected mid-gastrointestinal bleeding (n = 12), Crohn's disease (n = 17), abdominal pain (n = 8), and abdominal tumor (n = 4). The mean procedure time was 62.8 +/- 20.2 minutes and 70.4 +/- 19.3 minutes for the oral and anal routes, respectively. Among 24 patients in whom total enteroscopy was attempted, the entire small intestine was explored in 6. CONCLUSION: SBE is not only easy to perform, due to the single balloon, but it can also safely examine the deep small intestine. Therefore, SBE may be a useful diagnostic and therapeutic tool in addition to DBE for investigating suspected small bowel disease.
Subject(s)
Endoscopy, Gastrointestinal/methods , Intestinal Diseases/diagnosis , Intestinal Diseases/therapy , Intestine, Small , Abdominal Neoplasms/diagnosis , Abdominal Neoplasms/therapy , Abdominal Pain/diagnosis , Abdominal Pain/therapy , Adult , Aged , Aged, 80 and over , Cohort Studies , Crohn Disease/diagnosis , Crohn Disease/therapy , Equipment Design , Equipment Safety , Female , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/therapy , Humans , Japan , Male , Middle Aged , Reproducibility of Results , Risk Assessment , Sensitivity and Specificity , Treatment OutcomeABSTRACT
BACKGROUND: Azathioprine (AZA) is the drug recommended for the continuation of immunosuppressive treatment after renal transplant in women during pregnancy. CASE REPORT: A 37-year-old Japanese female developed agranulocytosis and severe alopecia after initiation of AZA (50 mg), used as an alternative to mycophenolate mofetil (MMF, 1000 mg) therapy in anticipation of a planned pregnancy. Within 4 days of the initiation of AZA therapy, the patient developed a high fever, leucopenia, and cranial alopecia. Genetic testing revealed a homozygous polymorphism of NUDT15 (rs116855232, NM_018283.3:c.415C>T: p.Arg139Cys), which has previously been identified as a risk factor for AZA-related complications in patients with inflammatory bowel disease. CONCLUSION: Genetic screening for NUDT15 could contribute to the prevention of serious adverse reactions to AZA and provide the opportunity for personalized medicine. Identification of a safe alternative to MMF during pregnancy after a renal transplant is a problem to be resolved in the future.
Subject(s)
Azathioprine/adverse effects , Immunosuppressive Agents/adverse effects , Kidney Transplantation , Pyrophosphatases/genetics , Adult , Agranulocytosis/chemically induced , Alopecia/chemically induced , Female , Graft Rejection/prevention & control , Homozygote , Humans , Kidney Transplantation/methods , Polymorphism, Single Nucleotide/genetics , Pregnancy , Risk FactorsABSTRACT
Lysine-specific demethylase 1 (LSD1) regulates gene expression by affecting histone modifications and is a promising target for acute myeloid leukemia (AML) with specific genetic abnormalities. Novel LSD1 inhibitors, NCD25 and NCD38, inhibited growth of MLL-AF9 leukemia as well as erythroleukemia, megakaryoblastic leukemia and myelodysplastic syndromes (MDSs) overt leukemia cells in the concentration range that normal hematopoiesis was spared. NCD25 and NCD38 invoked the myeloid development programs, hindered the MDS and AML oncogenic programs, and commonly upregulated 62 genes in several leukemia cells. NCD38 elevated H3K27ac level on enhancers of these LSD1 signature genes and newly activated ~500 super-enhancers. Upregulated genes with super-enhancer activation in erythroleukemia cells were enriched in leukocyte differentiation. Eleven genes including GFI1 and ERG, but not CEBPA, were identified as the LSD1 signature with super-enhancer activation. Super-enhancers of these genes were activated prior to induction of the transcripts and myeloid differentiation. Depletion of GFI1 attenuated myeloid differentiation by NCD38. Finally, a single administration of NCD38 causes the in vivo eradication of primary MDS-related leukemia cells with a complex karyotype. Together, NCD38 derepresses super-enhancers of hematopoietic regulators that are silenced abnormally by LSD1, attenuates leukemogenic programs and consequently exerts anti-leukemic effect against MDS-related leukemia with adverse outcome.
Subject(s)
Benzamides/pharmacology , Enhancer Elements, Genetic , Enzyme Inhibitors/pharmacology , Histone Demethylases/antagonists & inhibitors , Leukemia/pathology , Myelodysplastic Syndromes/complications , Animals , Cell Division/drug effects , Cell Line, Tumor , Humans , Karyotyping , Leukemia/etiology , Leukemia/genetics , Mice , Mice, Inbred NODABSTRACT
The human major histocompatibility complex class I chain-related A gene (MICA) and the MICB gene are newly identified members of the major histocompatibility complex class I chain-related gene family. We demonstrate here that oxidative stress, induced by H(2)O(2), promoted MICA (2.2-fold) and MICB (3.8-fold) gene expression using the human colon carcinoma cell line (CaCo-2) and semi-quantitative RT-PCR.
Subject(s)
Caco-2 Cells/metabolism , Histocompatibility Antigens Class I/biosynthesis , Membrane Proteins/metabolism , Oxidative Stress , Gene Expression Regulation , Histocompatibility Antigens Class I/genetics , Humans , Hydrogen Peroxide , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
The expression of S100A6 (also known as Calcyclin/2A9/ 5B10/PRA) in surgically resected human colorectal adenocarcinomas was examined to investigate whether S100A6 plays a role in the malignancy of human tumor cells. Western blot analysis using the lysates from colorectal adenocarcinomas and adjacent normal mucosa from 10 patients revealed that the average S100A6 level of adenocarcinomas was significantly higher (about 2.4-fold) than that of normal mucosa. Immunohistochemical analysis using formalin-fixed paraffin-embedded surgical specimens and monoclonal anti-S100A6 antibody (mAbA6) demonstrated that 2(5%) of 42 normal mucosa and 6 (46%) of 13 adenoma specimens were mAbA6-positive and showed granular staining localized at the supranuclear regions of epithelial cells, whereas 23 (55%) of 42 adenocarcinomas and 13 (100%) of 13 carcinoma cells that metastasized to the liver were mAbA6-positive and showed diffuse cytoplasmic staining. A significant correlation between S100A6 expression and Dukes' tumor stage or lymphatic permeation but not with other clinicopathological factors was shown. S100A6 was stained more intensely in peripheral portions than in central portions of adenocarcinomas, whereas Ki-67 (a growth marker) was stained equally in these two portions. These results suggest that S100A6 may be involved in the progression and invasive process of human colorectal adenocarcinomas.
Subject(s)
Adenocarcinoma/pathology , Cell Cycle Proteins , Colorectal Neoplasms/pathology , S100 Proteins/analysis , Adenocarcinoma/chemistry , Adenocarcinoma/surgery , Adenoma/chemistry , Adenoma/pathology , Blotting, Western , Colonic Neoplasms/chemistry , Colonic Neoplasms/pathology , Colorectal Neoplasms/chemistry , Colorectal Neoplasms/surgery , Epidermal Growth Factor/analysis , Female , Humans , Immunohistochemistry , Intestinal Mucosa/chemistry , Intestinal Mucosa/pathology , Male , Middle Aged , Neoplasm Staging , Rectal Neoplasms/chemistry , Rectal Neoplasms/pathology , S100 Calcium Binding Protein A6ABSTRACT
The plasma inhibin concentrations in 190 normal pregnant women at 5-40 weeks gestation and in 4 puerperal women were measured by a specific RIA for human inhibin. The average plasma inhibin concentrations in pregnant women throughout pregnancy (minimum, 2.25 +/- 0.48 IU/mL at 17 weeks gestation; maximum, 24.15 +/- 6.99 IU/mL at 39 weeks gestation) were much higher than those in nonpregnant women with a normal menstrual cycle (0.46 +/- 0.04 IU/mL in the midfollicular phase and 2.02 +/- 0.47 IU/mL in the midluteal phase). The inhibin concentrations were already high at 5 weeks gestation (7.54 +/- 1.10 IU/mL) and rose to peak at 8-10 weeks gestation. The concentrations then decreased and remained relatively low during 14-30 weeks gestation, but rose again during the third trimester. The inhibin concentrations decreased to undetectable levels after delivery. Immunoreactive inhibin was demonstrated in the corpus luteum and term placental extracts, and the dose-response curves were parallel to an inhibin preparation from human follicular fluid. Immunoreactive inhibin concentrations were also high in both the umbilical vein and artery (7.77 +/- 0.80 and 7.84 +/- 0.78 IU/mL, respectively). These observations suggest that both the corpus luteum and placenta are likely sources of inhibin.
Subject(s)
Inhibins/blood , Pregnancy/blood , Adult , Female , Fetal Blood/analysis , Follicle Stimulating Hormone/analysis , Gestational Age , Humans , Inhibins/immunology , Luteal Cells/analysis , Menstrual Cycle/blood , Middle Aged , Placenta/analysis , Pregnancy Trimester, Third , RadioimmunoassayABSTRACT
UNLABELLED: To evaluate the influence of blood substrate levels on myocardial uptake of 123I-labeled beta-methyl-iodophenyl-pentadecanoic acid (BMIPP), we examined the correlation between myocardial BMIPP uptake and blood levels of free fatty acid (FFA), glucose, insulin, triglyceride and total cholesterol. METHODS: In 180 patients, venous blood samples were obtained, and the early and late myocardial uptakes (MU15 and MU150) were determined on planar images at 15 and 150 min after injection at rest, respectively, and the clearance rate of BMIPP from the myocardium was calculated. Dynamic SPECT with BMIPP, PET with [18F]fluoro-deoxyglucose and determination of myocardial carnitine contents were performed in 15, 1 and 3 patients, respectively. RESULTS: In the 180 patients, MU15 correlated with blood insulin (r = 0.22, p = 0.005) and FFA (r = -0.19, p = 0.02) levels, whereas MU150 did not correlate with blood levels of any variables that were measured (p > 0.05). The clearance rate correlated with blood insulin (r = 0.28, p < 0.001), glucose (r = 0.17, p = 0.03) and FFA (r = -0.40; p < 0.001) levels. The correlations were, however, weak, and five patients (2.8%) with no myocardial BMIPP uptake, all of whom had anterior myocardial infaction, had no characteristics regarding the blood substrate levels. Although dynamic SPECT demonstrated rapid myocardial extraction of BMIPP in 13 patients with myocardial BMIPP uptake, it demonstrated no myocardial BMIPP extraction in two patients with no myocardial BMIPP uptake. One of the five patients with no myocardial BMIPP uptake showed increased myocardial [18F]fluorodeoxyglucose uptake and decreased myocardial carnitine content. CONCLUSION: The influence of blood substrate levels on myocardial BMIPP uptake is not very significant, although high serum FFA levels may be associated with slow clearance of BMIPP from the myocardium. The complete absence of myocardial BMIPP uptake is not rare and may not be associated with changes in blood substrate levels or early back diffusion of BMIPP.
Subject(s)
Fatty Acids/pharmacokinetics , Heart/diagnostic imaging , Iodine Radioisotopes , Iodobenzenes/pharmacokinetics , Myocardium/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Blood Glucose/analysis , Carnitine/metabolism , Child , Cholesterol/blood , Deoxyglucose/analogs & derivatives , Deoxyglucose/pharmacokinetics , Fatty Acids, Nonesterified/blood , Female , Fluorine Radioisotopes , Fluorodeoxyglucose F18 , Humans , Insulin/blood , Male , Middle Aged , Tomography, Emission-Computed , Tomography, Emission-Computed, Single-Photon , Triglycerides/bloodABSTRACT
The germinal center (GC) is a compartment for B cell differentiation and proliferation. Interleukin (IL)-4 has been considered essential for GC functioning. To define the role of IL-4 in GC reaction, immunohistology of draining lymph nodes (LNs) of IL-4 gene-targeted (IL-4(-/-)) mice was performed during secondary immune response. IL-4(-/-) mice were immunized with ovalbumin emulsified in Freund' complete adjuvant. Final antigen challenge was done 4 weeks later. IL-4(-/-) mice had a higher production of IgG2a and IgG2b and a lower production of IgG1 than those in wild-type (WT) mice. In comparison with WT mice, LNs of IL-4(-/-) mice on days 4 and 7 after final antigen challenge were larger and contained a markedly greater number of GCs, which showed marked size variations with a large number of small GCs and a small number of markedly large GCs. By day 14, the number of GCs decreased to the same level as that in WT mice. However, the LN size in IL-4(-/-) mice was still larger than that in WT mice due to the presence of markedly large GCs. Although well-developed complement receptor(+) follicular dendritic cell (FDC) networks were present in GCs of IL-4(-/-) mice, no FDCs of mature phenotype (CD23(+)) were observed in many of the small GCs. In conclusion, the absence of IL-4 enhanced GC reaction and specific antibody response of Th1-type. IL-4 may play an important role in inducing the appropriate magnitude of humoral immune response.
Subject(s)
Germinal Center/immunology , Interleukin-4/immunology , Animals , Dendritic Cells, Follicular/immunology , Immunization, Secondary , Immunoglobulin G/blood , Interferon-gamma/genetics , Interferon-gamma/immunology , Interleukin-4/genetics , Lymph Nodes/anatomy & histology , Lymph Nodes/cytology , Lymph Nodes/immunology , Mice , Mice, Inbred BALB C , Mice, Knockout , Ovalbumin/immunology , Receptors, Complement/immunology , Receptors, IgE/immunologyABSTRACT
Serum diamine oxidase (DAO) activity is very low, but is considered to reflect quantitative changes in small intestinal mass. Therefore, we measured DAO activity during chemotherapy in patients with hematological malignancies in order to evaluate mucosal injury. DAO activity decreased from 1-3 weeks after chemotherapy but returned to initial levels after 4 weeks. As the dosage of anti-cancer drugs increased, DAO activity decreased more, but its activity was not related to other parameters. These findings suggest that serum DAO could be used as an indicator of mucosal injury during chemotherapy.
Subject(s)
Amine Oxidase (Copper-Containing)/blood , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/enzymology , Intestinal Mucosa/enzymology , Adult , Aged , Blood Proteins/metabolism , Bone Marrow Transplantation , Cholinesterases/blood , Dose-Response Relationship, Drug , Female , Humans , Intestinal Mucosa/drug effects , Intestine, Small/drug effects , Intestine, Small/enzymology , Leukemia/drug therapy , Leukemia/enzymology , Leukocyte Count/drug effects , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/enzymology , Male , Middle Aged , Serum Albumin/metabolism , Time FactorsABSTRACT
Caveolae are vesicular invaginations of the plasma membrane that act as a scaffold of the assembly of many classes of signaling molecules. Caveolins are the principal structural component of caveolae membranes, and three distinct forms of caveolins have been identified: caveolin-1, caveolin-2, and caveolin-3. In this study, we evaluated the changes in the caveolin-1 and caveolin-2 expression in the inflamed mucosa of patients with IBD. Tissue samples were obtained endoscopically from patients with ulcerative colitis (UC) (n = 18), Crohn's disease (n = 10) and ischemic colitis (n = 8). Normal colorectal tissues were also obtained (n = 15). The caveolin expression was evaluated by standard immunohistochemical procedure. In normal colonic mucosa, caveolin-1 expression was detected in the smooth-muscle cells of the muscularis mucosae and the endothelial cells, but caveolin-2 expression was not detected. In the inflamed mucosa of patients with active UC, caveolin-2 expression was clearly detectable as small scattered foci on the luminal surfaces of epithelial cells, but caveolin-1 expression was similar to that in normal mucosa. Caveolin-2 expression increased in accordance with the disease activity of UC. This enhanced caveolin-2 expression was not detected in active Crohn's disease or ischemic colitis. In conclusion, we demonstrated that the epithelial expression of caveolin-2 is markedly enhanced in the inflamed mucosa of patients with UC. It is likely that the enhanced caveolin-2 expression in patients with UC was associated with the altered signal transductions in the intestinal epithelial cells. Furthermore, our results suggest that there are differences in the phenotypic features of epithelial cells between UC and Crohn's disease.
Subject(s)
Caveolins/analysis , Colitis, Ulcerative/pathology , Intestinal Mucosa/pathology , Caveolin 1 , Caveolin 2 , Colitis, Ulcerative/metabolism , Crohn Disease/pathology , Humans , Immunohistochemistry , Intestinal Mucosa/chemistryABSTRACT
The third complement component, C3, is an important factor in the host defense mechanism in which monocytes/macrophages participate as the primary phagocytes. Monocytes/macrophages are the principal extrahepatic producers of C3, and this C3 production is thought to be regulated by several cytokines. In the present study, we demonstrated that human macrophage colony-stimulating factor (M-CSF) enhanced C3 production by human peripheral monocytes in serum-free culture. Analytical immunoblot and ELISA showed that the presence of M-CSF increased the production of intracellular pro-C3 and extracellular C3 for 24 h in a dose-dependent manner. To confirm the rapid effect of M-CSF on C3 production, we performed metabolic labeling of C3 with [35S]methionine. The production of [35S]C3 for the first 6 h in the presence of M-CSF was also increased as compared to that in the absence of M-CSF. In addition to the previously reported effects of M-CSF on monocytes/macrophages, such as the enhancement of C3 receptor expression and C3 receptor-mediated phagocytosis, we consider that the effects of M-CSF demonstrated in this study are of importance in the local immune system organization of C3 and monocytes/macrophages.
Subject(s)
Complement C3/biosynthesis , Macrophage Colony-Stimulating Factor/pharmacology , Macrophages/drug effects , Monocytes/drug effects , Humans , Macrophages/metabolism , Monocytes/metabolismABSTRACT
Trisomy 4 has been identified previously as a chromosome abnormality associated with acute nonlymphocytic leukemia (ANLL) with myelomonocytic lineage and in myelodysplastic syndromes (MDS). We report a case of acute lymphocytic leukemia (ALL) (French-American-British, FAB L1) in a 42-year-old Japanese man, with trisomy 4 as the sole chromosomal anomaly. Immunophenotypically, the leukemic blasts demonstrated reactivity with CD2, CD5, and CD7 and indicated on early stage of T cell.